» Articles » PMID: 24300302

Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2013 Dec 5
PMID 24300302
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

After the launch of dipeptidyl peptidase-4 (DPP-4), a new oral hypoglycemic drug (OHD), in December 2009, severe hypoglycemia cases were reported in Japan. Although the definite cause was unknown, co-administration with sulfonylureas (SU) was suspected as one of the potential risk factors. The Japan Association for Diabetes Education and Care (JADEC) released a recommendation in April 2010 to lower the dose of three major SUs (glimepiride, glibenclamide, and gliclazide) when adding a DPP-4 inhibitor. To evaluate the effectiveness of this risk minimization action along with labeling changes, dispensing records for 114,263 patients prescribed OHDs between December 2008 and December 2010 were identified in the Nihon-Chouzai pharmacy claims database. The adherence to the recommended dosing of SU co-prescribed with DPP-4 inhibitors increased from 46.3% before to 63.8% after the JADEC recommendation (p < 0.01 by time-series analysis), while no change was found in those for SU monotherapy and SU with other OHD co-prescriptions. The adherence was significantly worse for those receiving a glibenclamide prescription. The JADEC recommendation, along with labeling changes, appeared to have a favorable effect on the risk minimization action in Japan. In these instances, a pharmacy claims database can be a useful tool to evaluate risk minimization actions.

Citing Articles

Changes in prescription patterns and doses of oral antidiabetic drugs in Japanese patients with type 2 diabetes (JDDM70).

Shirabe S, Yamazaki K, Oishi M, Arai K, Yagi N, Sato M J Diabetes Investig. 2022; 14(1):75-80.

PMID: 36268571 PMC: 9807151. DOI: 10.1111/jdi.13922.


Seasonal Variation in Severe Glucose-lowering Drug-induced Hypoglycemia in Patients with Type 2 Diabetes.

Minamoto-Higashioka M, Kawamura R, Umakoshi H, Yokomoto-Umakoshi M, Utsunomiya D, Osawa H Intern Med. 2019; 58(8):1067-1072.

PMID: 30626812 PMC: 6522416. DOI: 10.2169/internalmedicine.1360-18.


The RIMES Statement: A Checklist to Assess the Quality of Studies Evaluating Risk Minimization Programs for Medicinal Products.

Smith M, Russell A, Bahri P, Mol P, Frise S, Freeman E Drug Saf. 2017; 41(4):389-401.

PMID: 29218682 PMC: 5878197. DOI: 10.1007/s40264-017-0619-x.


Measuring the impact of medicines regulatory interventions - Systematic review and methodological considerations.

Goedecke T, Morales D, Pacurariu A, Kurz X Br J Clin Pharmacol. 2017; 84(3):419-433.

PMID: 29105853 PMC: 5809349. DOI: 10.1111/bcp.13469.


Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin.

Kim Y, Yoo W, Hong E, Ku E, Park K, Lim S Diabetes Metab J. 2015; 39(6):489-97.

PMID: 26616595 PMC: 4696985. DOI: 10.4093/dmj.2015.39.6.489.


References
1.
Ooba N, Yamaguchi T, Kubota K . The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008. Drug Saf. 2011; 34(4):329-38. DOI: 10.2165/11588230-000000000-00000. View

2.
Wilkinson J, Force R, Cady P . Impact of safety warnings on drug utilization: marketplace life span of cisapride and troglitazone. Pharmacotherapy. 2004; 24(8):978-86. DOI: 10.1592/phco.24.11.978.36136. View

3.
Kikuchi M, Abe N, Kato M, Terao S, Mimori N, Tachibana H . Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2009; 83(2):233-40. DOI: 10.1016/j.diabres.2008.10.006. View

4.
Foulon V, Svala A, Koskinen H, Chen T, Saastamoinen L, Bell J . Impact of regulatory safety warnings on the use of antidepressants among children and adolescents in Finland. J Child Adolesc Psychopharmacol. 2010; 20(2):145-50. DOI: 10.1089/cap.2009.0040. View

5.
Shatin D, Gardner J, Stergachis A, Blough D, Graham D . Impact of mailed warning to prescribers on the co-prescription of tramadol and antidepressants. Pharmacoepidemiol Drug Saf. 2004; 14(3):149-54. DOI: 10.1002/pds.961. View